Datapoint: Centene to Sell Two Specialty Pharma Businesses

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 10

Centene Corp. last week entered an agreement to sell two of its recent specialty pharmacy acquisitions, Magellan Rx and PANTHERx Rare, in separate deals totaling $2.8 billion. Magellan Rx will be sold to Blues PBM powerhouse Prime Therapeutics, while will go to a consortium of The Vistria Group, General Atlantic, and Nautic Partners, pending regulatory approval. Centene is currently the fourth-largest insurer in the U.S., with 21,213,845 members.

Source: AIS’s Directory of Health Plans

0
0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 6

Datapoint: New Mexico Cancels Medicaid RFP

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 2

Datapoint: Blue Shield of California Launches Virtual-First Plan

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 1

Datapoint: FDA Approves Lilly’s Jaypirca in Blood Cancer

Read More
panalgo-building-an-effective-analytics-team

The Latest

directory-of-health-plans-test-drive-directory-of-health-plans-ad

Meet Our Reporters

Tags

AIS's Directory of Health Plans

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today